Author

M. M. Ittmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:metabolomics· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

D. E. Frigo· 3 shared J. J. Han· 3 shared M. M. Murray· 3 shared T. L. Pulliam· 3 shared D. Awad· 2 shared J. J. Ackroyd· 2 shared A. Grattoni· 1 shared A. H. Pham· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. E. Frigo

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Role of Adenosine Deaminase in Prostate Cancer Progression

C. Charles, S. M. Lloyd, D. W. B. Piyarathna, J. Gohlke, U. Rasaily, V. Putluri, B. W. Simons, A. Zaslavsky, S. Nallandhighal, N. Palanisamy, N. Navone, J. A. Jones, M. M. Ittmann, N. Putluri, D. R. Rowley, , A. Sreekumar

This study identifies adenosine deaminase (ADA) as a driver of prostate cancer progression and metastasis through metabolomics and in vitro/in vivo experiments.

bioRxiv · Aug 9, 2023 · PreprintCancer Biology

Ultra-long-acting refillable nanofluidic implant confers full protection against SHIV infection in non-human primates

F. P. Pons-Faudoa, N. Di Trani, S. Capuani, J. N. Campa-Carranza, B. Nehete, S. Sharma, K. A. Shelton, L. R. Bushman, F. Abdelmawla, M. Williams, L. Roon, D. Nerguizian, C. Y. X. Chua, M. M. Ittmann, J. E. Nichols, , A. Grattoni

An ultra-long-acting refillable nanofluidic implant sustained islatravir levels in non-human primates for 20 months and provided 100% protection against SHIV infection.

bioRxiv · Dec 15, 2022 · PreprintBioengineering

Adipose triglyceride lipase is regulated by CAMKK2-AMPK signaling and drives advanced prostate cancer

D. Awad, T. L. Pulliam, M. L. Spradlin, P. H.-A. Cao, E. Subramani, T. V. Tellman, C. F. Ribeiro, H. Pakula, J. J. Ackroyd, M. M. Murray, J. J. Han, B. Piyarathna, J. M. Drake, M. M. Ittmann, C. Coarfa, , D. E. Frigo

This study identifies ATGL as a CAMKK2-AMPK target that promotes CRPC progression by enhancing lipase activity and metabolic plasticity, suggesting it as a therapeutic target.

bioRxiv · Nov 2, 2022 · PreprintCancer Biology

Systemic ablation of Camkk2 impairs metastatic colonization and improves insulin sensitivity in TRAMP mice: Evidence for cancer cell-extrinsic CAMKK2 functions in prostate cancer

T. L. Pulliam, D. Awad, J. J. Han, M. M. Murray, J. J. Ackroyd, P. Goli, J. S. Oakhill, J. W. Scott, M. M. Ittmann, D. E. Frigo

This study shows that deleting Camkk2 in TRAMP mice reduces metastasis and improves insulin sensitivity, suggesting CAMKK2 has non-autonomous roles in prostate cancer progression.

bioRxiv · Mar 28, 2022Cancer Biology

Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling

C. Lin, A. M. Blessing, T. L. Pulliam, Y. Shi, S. R. Wilkenfeld, J. J. Han, M. M. Murray, A. H. Pham, K. Duong, S. N. Brun, R. J. Shaw, M. M. Ittmann, D. E. Frigo

This study shows that inhibiting CAMKK2 blocks autophagy and slows castration-resistant prostate cancer by disrupting AMPK-ULK1 signaling.

bioRxiv · Jun 2, 2020Cancer Biology